Compare Mesoblast Limited (MESO) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ProShares UltraPro S&P500 — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: ProShares UltraPro S&P500 is far larger — about 3.2× Mesoblast Limited's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and ProShares UltraPro S&P500 for 29 Days on average.
| MESO | UPRO | |
|---|---|---|
Market Cap | $1.75B | $5.55B |
Volume | 239,027 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.96 | $157.66 |
52-Week Low | $13.19 | $89.29 |
Typical Hold Time | 15 Days | 29 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
UPRO trades at $155.73, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026.
The outlook is cautiously optimistic due to bullish technical trends, but the absence of fundamental metrics like P/E and ROE increases reliance on market sentiment. Risks include S&P 500 volatility and profit growth concerns highlighted in recent news. Investors should seek updated financials for a complete view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
